Matthew Nock

Professor of Psychology

Data updated

Papers

9 publications

Trials

0 clinical trials

Links

Research Footprint

Matthew Nock appears in 9 tracked papers (2019–2023), most studied alongside Psilocybin, LSD and Mescaline, across Substance Use Disorders (SUD), Suicidality and Public Health, Prevention & Behaviour Change.

Most-cited paper: Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial (178 citations).

Frequent co-authors: George Jones, Daniel Ionescu and Maurizio Fava.

Background & Research

Matthew K. Nock is Professor of Psychology at Harvard University and a senior clinical-scientist whose primary career contributions have been in the epidemiology, measurement and prediction of suicide, self-injury and related psychopathology. Over the past several years he has extended his methodological expertise to population-level investigations of psychedelic exposures, co-authoring multiple large nationally representative survey analyses that examine associations between lifetime use of classic psychedelics (including psilocybin and LSD), MDMA/ecstasy and a range of outcomes such as major depressive episodes, nicotine dependence, opioid and cocaine use disorders, and criminal-justice involvement.

Nock's work in psychedelic science is characterised by careful attention to sampling, confounding control and moderation (notably by race and ethnicity), and by situating observational findings within broader clinical and public-health contexts. He has emphasised statistical rigour and transparency in analyses of substance-use and mental-health correlates of psychedelic use. Disclosure: Nock receives publication royalties from Macmillan, Pearson and UpToDate.

Affiliations

Institutions, companies, and organisations Matthew Nock is associated with.